Leukotriene receptor antagonists in the treatment of asthma

Pharmacotherapy. 2001 Mar;21(3 Pt 2):34S-37S. doi: 10.1592/phco.21.4.34s.34262.

Abstract

The role of leukotriene receptor antagonists in the treatment of persistent asthma is in evolution. Pivotal 8-12-week, randomized, controlled trials in both adults and children have shown efficacy, as defined by standard asthma outcomes. Tolerance to therapy did not develop, nor did rebound worsening of asthma symptoms once therapy was withdrawn. In a comparator trial of montelukast versus beclomethasone, the average percentage change from baseline in forced expiratory volume in 1 second was greater with the inhaled corticosteroid preparation; however, improvements in other asthma outcomes were similar. There was considerable heterogeneity of pulmonary response with both treatments, with good and poor responders in both groups. In an open-label, crossover comparison of montelukast versus cromolyn, both parents and children preferred montelukast, thus regimen adherence was greater with montelukast. Additional long-term, randomized, controlled trials will define the effectiveness of leukotriene receptor antagonists compared with established controllers, thus determining the leukotriene receptor antagonists' place in asthma management.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / drug therapy*
  • Asthma / immunology
  • Child
  • Histamine H1 Antagonists / therapeutic use*
  • Humans
  • Leukotriene Antagonists* / immunology
  • Leukotriene Antagonists* / therapeutic use*
  • Leukotrienes / immunology
  • Middle Aged
  • Randomized Controlled Trials as Topic

Substances

  • Anti-Asthmatic Agents
  • Histamine H1 Antagonists
  • Leukotriene Antagonists
  • Leukotrienes